

Synergistic Anticancer Effect of a Combination of Berbamine and Arcyriaflavin A against Glioblastoma Stem-like Cells

Jang Mi Han ¹ and Hye Jin Jung ^{1,2,3,*}

¹ Department of Life Science and Biochemical Engineering, Graduate School, Sun Moon University, Asan 31460, Republic of Korea

² Department of Pharmaceutical Engineering and Biotechnology, Sun Moon University, Asan 31460, Republic of Korea

³ Genome-Based BioIT Convergence Institute, Sun Moon University, Asan 31460, Republic of Korea

* Correspondence: poka96@sunmoon.ac.kr; Tel.: +82-41-530-2354; Fax: +82-41-530-2939




Figure S1. Effect of berbamine and ArcA on the viability of GSCs. (A) U87MG-derived GSCs were treated with the indicated concentrations of berbamine or ArcA for 7 days. (B) C6-derived GSCs were treated with the indicated concentrations of berbamine or ArcA for 7 days. Cell viability was measured using the CellTiter-Glo[®] luminescent assay system. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ vs. the control.




Figure S2. Effect of combined treatment with berbamine and ArcA on the proliferation of GSCs. U87MG- and C6-derived GSCs were treated with 10 μ M berbamine and 20 μ M ArcA for 7 days and cell proliferation was measured using the ATP-monitoring luminescence assay. *** $p < 0.001$ vs. the compound alone.




Figure S3. Effect of combined treatment with berberine and ArcA on the cell cycle in GSCs. (A) U87MG- and (B) C6-derived GSCs were treated with berberine (10 μ M) and ArcA (20 μ M) for 4, 8, and 12 h. Cell cycle distribution was detected using a Muse Cell Analyzer with Muse® Cell Cycle kit.